|
Schizophrenia
Citations 81-90 of 318 total displayed.
|
Past content
(since Jan 1998):
|
- Commentaries
The Surprisingly Rich Contours of Schizophrenia Epidemiology
- John J. McGrath
Arch Gen Psychiatry 2007; 64: 14-16.
[Extract]
[Full text]
[PDF]
- Original Articles
Elevated Prenatal Homocysteine Levels as a Risk Factor for Schizophrenia
- Alan S. Brown; Teodoro Bottiglieri; Catherine A. Schaefer; Charles P. Quesenberry Jr; Liyan Liu; Michaeline Bresnahan; Ezra S. Susser
Arch Gen Psychiatry 2007; 64: 31-39.
[Abstract]
[Full text]
[PDF]
- Original Articles
Preserved Subliminal Processing and Impaired Conscious Access in Schizophrenia
- Antoine Del Cul; Stanislas Dehaene; Marion Leboyer
Arch Gen Psychiatry 2006; 63: 1313-1323.
[Abstract]
[Full text]
[PDF]
- Original Articles
Startle Gating Deficits in a Large Cohort of Patients With Schizophrenia: Relationship to Medications, Symptoms, Neurocognition, and Level of Function
- Neal R. Swerdlow; Gregory A. Light; Kristin S. Cadenhead; Joyce Sprock; Ming H. Hsieh; David L. Braff
Arch Gen Psychiatry 2006; 63: 1325-1335.
[Abstract]
[Full text]
[PDF]
- Original Articles
Early Visual Sensory Deficits as Endophenotypes for Schizophrenia: High-Density Electrical Mapping in Clinically Unaffected First-Degree Relatives
- Sherlyn Yeap; Simon P. Kelly; Pejman Sehatpour; Elena Magno; Daniel C. Javitt; Hugh Garavan; Jogin H. Thakore; John J. Foxe
Arch Gen Psychiatry 2006; 63: 1180-1188.
[Abstract]
[Full text]
[PDF]
- Original Articles
Adverse Effects of Risperidone on Spatial Working Memory in First-Episode Schizophrenia
- James L. Reilly; Margret S. H. Harris; Matcheri S. Keshavan; John A. Sweeney
Arch Gen Psychiatry 2006; 63: 1189-1197.
[Abstract]
[Full text]
[PDF]
- Commentaries
Comparative Effectiveness of Antipsychotic Drugs: A Commentary on Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)
- Jeffrey A. Lieberman
Arch Gen Psychiatry 2006; 63: 1069-1072.
[Extract]
[Full text]
[PDF]
- Commentaries
Outcomes, Costs, and Policy Caution: A Commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
- Robert A. Rosenheck
Arch Gen Psychiatry 2006; 63: 1074-1076.
[Extract]
[Full text]
[PDF]
- Original Articles
Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
- Peter B. Jones; Thomas R. E. Barnes; Linda Davies; Graham Dunn; Helen Lloyd; Karen P. Hayhurst; Robin M. Murray; Alison Markwick; Shôn W. Lewis
Arch Gen Psychiatry 2006; 63: 1079-1087.
[Abstract]
[Full text]
[PDF]
- Original Articles
Prediction of Functional Outcome 18 Months After a First Psychotic Episode: A Proton Magnetic Resonance Spectroscopy Study
- Stephen J. Wood; Gregor E. Berger; Martin Lambert; Phillipe Conus; Dennis Velakoulis; Geoffrey W. Stuart; Patricia Desmond; Patrick D. McGorry; Christos Pantelis
Arch Gen Psychiatry 2006; 63: 969-976.
[Abstract]
[Full text]
[PDF]
|
|
